Evaluation of the Efficacy and Tolerability of Detralex in Patients With Chronic Venous Edema in Real Clinical Practice

Inclusion Criteria: * Age 18 years old or above * Written informed consent * Patient did not receive treatment with venoactive drugs within the past 4 weeks prior to the inclusion in the study * Diagnosis of chronic venous disease of class C3 (CEAP) * Decision of an attending physician to prescribe Detralex. Exclusion Criteria: * Age below 18 years old * Written informed consent is not obtained * History of alcohol or drug abuse or use of narcotic drugs * History of allergic reaction to diosmin or any other venoactive agent, or their intolerance * History of allergic reaction to anesthetics and/or sclerosing agents * Chronic venous disease of СЕАР class C0-С2 or class С4-С6 * Lymphatic edema of the lower extremities * Secondary varicose veins, angiodysplasia, or neoplasia * Arterial disease (ankle-brachial index \<0.9) * Infection within the past 6 weeks * Any of the following concomitant diseases, which can affect the results: * Connective tissue disease (including rheumatoid arthritis), arthritis * Heart failure * Intermittent claudication (peripheral artery disease) * Diseases of the bones or joints of the lower extremities * Malignancy * Treatment with drugs potentially causing leg edema (calcium channel blockers, hormonal drugs, NSAIDs, etc.) * History of deep vein thrombosis (within the past year) * History of superficial thrombophlebitis (within the past 3 months) * Patient cannot walk (regardless of the cause) * Obesity or body mass index \[BMI\] \>30 kg/m2 \[BMI = body mass (kg)/height (m)2\] * Predictable poor adherence to treatment * Participation of the patient in the intervention study within the previous 3 months * For women: pregnancy or breastfeeding, the desire to become pregnant within at least 2 months after the study * Patient cannot attend a follow-up visit * Patients with a contraindication to diosmin-containing agents, including Detralex